Ken Griffin Liquidia Corp Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$8.9 - $14.11 $485,050 - $768,995	54,500 Added 33.46%	217,400 $2.17 Million
Q2 2024 Aug 14, 2024	SELL	$11.96 - $15.71 $455,676 - $598,551	-38,100 Reduced 18.96%	162,900 $1.95 Million
Q1 2024 May 15, 2024	SELL	$11.35 - $16.73 $59,020 - $86,996	-5,200 Reduced 2.52%	201,000 $2.96 Million
Q4 2023 Feb 14, 2024	BUY	$5.77 - $12.19 $625,468 - $1.32 Million	108,400 Added 110.84%	206,200 $2.48 Million
Q3 2023 Nov 14, 2023	BUY	$6.27 - $8.15 $43,263 - $56,235	6,900 Added 7.59%	97,800 $620,000
Q2 2023 Aug 14, 2023	SELL	$6.63 - $9.9 $49,725 - $74,250	-7,500 Reduced 7.62%	90,900 $713,000
Q1 2023 May 15, 2023	SELL	$5.72 - $7.91 $739,596 - $1.02 Million	-129,300 Reduced 56.79%	98,400 $679,000
Q4 2022 Feb 14, 2023	SELL	$4.68 - $6.54 $855,036 - $1.19 Million	-182,700 Reduced 44.52%	227,700 $1.45 Million
Q3 2022 Nov 14, 2022	BUY	$3.73 - $8.39 $1.38 Million - $3.1 Million	368,900 Added 888.92%	410,400 $2.23 Million

171

44.3M

1.55M

1.52M

Ticker LQDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 64,362,300
Market Cap $685M
Description
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil inje...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.